Incredibly excited to have matched to @StanfordMedRes and its physician-scientist training program! 🫀🩺 Best part of today? My 2 best buddies are also staying 😭 I am nothing without my village of friends, mentors, and family. #Match2023 #MedTwitter #CardioTwitter #Stanford

🚨 The long awaited DIGIT-HF Trial🚨 Does digitoxin improve outcomes in patients with HFrEF already on GDMT? 🫀 Results from this large, international RCT 🧵 #NEJM #ESCCongress @ESCardio @ACCinTouch @JACCJournals

Congrats to #StanDOM's @ATSandhu & Jason Hom! With collaborators from @aboutKP, @CedarsSinai & @MassGenBrigham, they secured a $5 million @American_Heart grant to advance #AI in #CardiovascularCare for better screening & treatment! https://t.co/81mNoOKoLM

We are excited to work with @StanfordDeptMed, @SmidtHeart, @mghliver, and @KPDOR with the support of @American_Heart to refine and prospectively evaluate AI opportunistic screening approaches for Cardiovascular-Kidney-Metabolic Health! Chronic Liver and Kidney Disease is common

In 1929, a 25-year-old doctor cut into his own arm and inserted a catheter into his heart. No permission, no supervision, just sheer defiance. He risked death to prove a theory no one believed. His insane gamble saved millions of lives. Here's his story:

PHARM-HF A&F evaluated audit & feedback vs. education to optimize HF meds in VA primary care pharmacists. ✅ Both arms improved GDMT 📈 A&F led to modest gains in MRAs ⚠️ GDMT uptake still lags, especially in rural areas! ( https://t.co/g0e6RndsKc) #HREV @JimmyZhengMD @ATSandhu

Alteplase Purge Solution for Impella 5.5 @asaiojournal @JimmyZhengMD Impella purge system occlusion, often referred to as “Impella thrombosis” not always associated w/worse pump fxn/failure. We describe a case w/unchanged hemodynamics/flow + review of lit. https://t.co/QD4pVUdXLr

One year as EiC of Heart Failure Reviews ( https://t.co/yw6ZI3qrOb)—what a journey! 📈 1M+ views and an IF approaching 5 (top quartile for cardiology)! Huge thanks to our amazing AEs & contributors for driving leading and innovative content in HF. Onward & upward in 2025! 🚀 #HREV

PRO-HF trial tested if routine use of KCCQ in HF clinics improves QoL. No significant difference in QoL or clinical outcomes at 1 year. Future work needed to optimize PRO integration. Summary in #HREV ( https://t.co/7i3er0b8kF). @me_canonico @marcsamsky @ATSandhu @JimmyZhengMD

🔥New #AHA24 #SimPub from #GWTG_HF 🇺🇸pts 🏥for HF w EF>40% 2021-2023....steady⤴️in #SGLT2i 🚨Yet,⬆️variation across 🏥....# of hospitals prescribing ZERO SGLT2i greater than # prescribing to majority of eligible pts 🤯 @DCRINews @JAMACardio @gcfmd https://t.co/Y0w7JX978z

I missed this: great @JACCJournals review on GU infxn w SGLT2i. SGLT2i is assoc w⬆️risk of GMI but NOT UTI or Fournier’s. #GDMTWorks for #HFrEF @UCSFCardiology @UCSFIMChiefs @gcfmd @SJGreene_md @AndrewJSauer https://t.co/bXoTbSRTxr

From @JAMACardio: Deep learning (DL) has the potential to reshape the field of cardiovascular imaging (CVI). This review aims to demystify the methodology and application of DL to CVI. https://t.co/99qP94ETL0

1/n We are excited to announce EchoPrime – the first echocardiography AI model capable of evaluating a full transthoracic echocardiogram study, identify the most relevant videos, and produce a comprehensive interpretation! Great work lead by @milos_ai, EchoPrime is the largest

Yikes‼️ Don't stop the GDMT💊 pre d/c that patients were taking on admission🚨 Sobering data from @JACCJournals & @Stanford_HF's @SunnyVMD @ATSandhu with @JimmyZhengMD 43-57% had no discernable medical contraindications to GDMT d/c‼️ @HFSA @escardio https://t.co/xxFRkJeuiR

Our partners at @ReprieveCardio are doing incredible work using Truveta Data. Really enjoyed reading this case study based on their presentation at this year’s Truveta Symposium. I find it simply absurd that prior to Truveta, the best source of real-world data on heart failure

I went to a talk during MIT’s career fair week circa 2017 where the speaker strongly made the case that over the next decade we would see an extreme oversupply of people with CS backgrounds but an extreme undersupply in domain experts with CS skills.

Here we looked at differences in quality for HF patients hospitalized in GWTG-HF. We found quality measure performance was similar across sex, race, ethnicity, and insurance in GWTG-HF hospitals with a few notable exceptions (e.g. CRT for women). 

Substantial drop-off in GDMT use prior to hospital discharge, half without clear contraindication. Among community-based hospitals, <50% patients discharged on triple/quadruple therapy. #GDMTWorks but only if patients take them 💊 https://t.co/saHWLFcf3a

Now in @JACCJournals #JACCHF @JimmyZhengMD @ATSandhu et al dive into large scale data on ADHF Diuretic Tx, 📌 Low overall weight loss (median 5lb) 📌 <20% use augmented diuretic tx What steps can be taken to implement effective practices ? 📎 https://t.co/wlRQTdRg7A

Finerenone meets primary endpoint in Phase III FINEARTS-HF🎉 ❤️ expanded treatment options for HFpEF! —> to be presented at ESC ‼️pending: the SPIRRT HFPEF trial with MRA ⁦@DCRINews⁩ ⁦@karolinskainst⁩ ⁦@UU_University⁩ ⁦@nih_nhlbi⁩

HF care still limited by inadequate diuresis🚾‼️ @Stanford_HF's @ATSandhu & @SunnyVMD & colleagues show: 1⃣ - weight ⬆️in 20% of encounters 2⃣ - adjunctive 💊in < 20%, despite their efficacy @ankeetbhatt @SJGreene_md @gcfmd @dranulala @FudimMarat https://t.co/h6VuGOZbow